2026 Biomedical Final Pitch Competition and Conference
5 月 23 日及 24 日
報名截止日期：5 月 19 日
聯合主辦方：
Boston Capital Investment Club (BCIC)
Hong Kong Science and Technology Parks Corporation (HKSTP)
誠邀您參加 2026 Biomedical Pitch Competition Final Pitch Event，搭建生物醫療初創企業與投資人及商業加速資源之間的橋梁。來自早期至中期階段、覆蓋制藥、醫療器械與診斷領域的 17 支 Finalist 團隊及 4 支 pitch-only 精選團隊將公開展示他們的項目。
精彩看點：
- 高層次觀眾群： 200+ Angel/VC 基金及行業領袖到場，尋找具有突破性的生物醫療解決方案。
- 多元合作機會： 探索潛在直接投資、licensing partnerships 及具有價值的戰略合作。
- 媒体曝光度： 借助覆蓋 20,000+ 受眾的媒体報道獲得廣泛关注。
深遠影響：近年成功案例
- Leveragen，2024 屆創賽獲獎團隊，已於 2026 年 3 月宣布與 Daiichi Sankyo 達成戰略合作
- 2025 屆一支獲獎團隊於 2026 年 1 月完成 NewCo spin-off 交易
- 2023 屆一支獲獎團隊於 2025 年底成功獲得後續融資（follow-on funding）
- Innovative Cellular Therapeutics (ICT)，2025 屆獲獎團隊之一，於 2025 年 11 月將 LYL273 (GCC19CART) 的全球權益出讓給 Lyell Immunopharma
2025 Pitch Competition 精選成果 Epigenic 成功融資 6,000 萬美元（Affinity Secures Funding） Groovy 完成融資（Groovy Secured Funding） 2026 年 1 月達成 NewCo 交易一例 Innovative Cellular Therapeutics (ICT) 於 2025 年 11 月達成 BD deal（ICT Sells Global Rights）
2024 Pitch Competition 精選成果 Rapafusyn 在美国成功融資 4,400 萬美元（BCIC Ecosystem｜創賽獲獎Rapafusyn融資4400萬美元） Agilis 自一家新加坡 family office 成功獲得 1,000 萬美元投資（Agilis Raised $10M） GV20 成功獲得超過 3,000 萬美元融資（GV20 Therapeutics Secured Funding over $30 Million） Affinity 完成 5,500 萬美元融資（Affinity Secures Funding） ImmViral 提交 IPO 申請（ImmViral Files for IPO） Leveragen 於 2026 年宣布與 Daiichi Sankyo 達成合作**（Leveragen BD Deal）**
2023 Pitch Competition 精選成果 Myrobalan 在參加 pitch competition 後 5 個月內於美国成功融資 2,400 萬美元（Myrobalan Therapeutics secures funding of $24 Million） 兩支初創公司分别完成 200 萬美元融資。 至少有一支初創團隊在亞洲落地。 一家公司於 2025 年底獲得 follow-on funding。
2022 Pitch Competition 精選成果 Amytrx 已融資 1,800 萬美元 ARIZ Precision Medicine 已融資 300 萬美元 Biostage 已融資 500 萬美元 至少兩家初創公司在亞洲落地
日期：
Day 1 — Final Pitch Day
5 月 23 日（星期六）8:30am – 5:30pm
Day 2 — Morning Conference
5 月 24 日（星期日）9:00am – 12:30
地點：現場參會需持票入場
Fish & Richardson P.C 會議廳（17 樓）
1 Marina Park Drive, Boston, MA 02210
議程：
參會形式：
In-Person（現場出席）： 名額有限，僅向受邀嘉賓及購票觀眾開放。
Virtual（線上參會）： 面向所有完成在線注冊的觀眾開放。
報名截止日期：5 月 19 日
請掃描下方二維碼完成報名
https://bcic.ticketspice.com/2026-biomedical-final-pitch-and-conference
如有任何問題，請發送郵件至：info@bcicglobal.org
聯合主辦方與贊助商
Boston Capital Investment Club (BCIC) — The Boston Capital Investment Club (BCIC) is a Massachusetts-registered non-profit organization serving nearly 10,000 professionals in finance, venture capital, and various technology industries. Beyond being a Boston-centered platform, the BCIC has grown to facilitate nationwide and international knowledge exchange across healthcare, finance, and related fields. Since 2022, the organization has hosted annual biomedical pitch competitions, empowering startups to secure over $300 million in collective funding.
Hong Kong Science and Technology Parks Corporation (HKSTP) — With a 20-year history of transforming lives through innovation, technology and entrepreneurship, HKSTP has been propelling success for the most creative minds and innovators around the globe, accelerating ambitions and delivering positive impact from Hong Kong to the Greater Bay Area and the world. https://www.hkstp.org/
Fish & Richardson P.C. — As the leading IP law firm, we help innovators change the world through our unmatched litigation, prosecution, and post-grant experience. Many of our 450+ attorneys and technology specialists are also scientists who are as comfortable in a lab or cleanroom as a courtroom or patent office.
Shanghai InnoStar — Shanghai InnoStar Bio-tech Co., Ltd. (InnoStar) was established in 2010. As a leading contract research organization, InnoStar has passed GLP inspections by US FDA and received GLP certification from NMPA, OECD, AAALAC, and CAP. Business scope covers screening and discovery, nonclinical pharmacodynamics, pharmacokinetics, safety evaluation, clinical sample bioanalysis, biomarkers and translational research. Listed on the STAR Market of Shanghai Stock Exchange (Stock code: 688710).
Porton Pharma Solutions Ltd — Founded in 2005, Porton is an internationally recognized pharmaceutical CDMO enabling global clients to optimize drug development and manufacturing across Small Molecules, Tides, Biologics and Conjugates (ADCs, AOCs, PDCs, RDCs), and Advanced Therapy Medicinal Products from pre-clinical to commercialization stages.
PanaCRO — A full-service clinical CRO founded in 2004, helping global biotech and biopharma companies accelerate clinical development in China. With 500+ employees, coverage across 20+ provinces, collaboration with 800+ research sites, PanaCRO provides end-to-end solutions from pre-IND/IND strategy and regulatory support to IITs, Phase I–III studies, NDA/BLA registration, and post-market real-world studies, combining deep local regulatory knowledge with international ICH-GCP standards.
Simcere Pharmaceutical Group — An innovation and R&D-driven pharmaceutical company focused on oncology, nervous system, autoimmune and antiinfection therapeutic areas, with the corporate mission of "providing today's patients with medicines of the future". Simcere has established several R&D innovation centers around the world, including the Boston Innovation Center in Cambridge.
Fenwick — A top law firm serving technology and life sciences clients with 500+ attorneys, nationally recognized for complex transactions, IP protection, M&A, and tax. Landmark work includes incorporating Apple, taking Oracle, eBay, and 180+ others public, and defending key biotech patents.
Final Pitch 評委（Judges）
- Hong Kong Science and Technology Parks Corporation (HKSTP)
- Northern Light Venture Capital (NLVC)
- TCG Crossover
- RA Capital
- Chugai Venture
- Kendall Capital Partners
- PagodaTree Partners
- Eisai Innovation, Inc
- HM Capital
媒体合作伙伴（Media Partners）
- Deep Blue
- SaiBaiLan
- E Drug
- Drug Times
- Gene Online
- Page Executive
- BoYao
- VC Beat
特别鸣謝以下機構對本次活動的推廣支持
· Harvard Life Lab · Harvard Innovation Labs · Harvard Wyss Institute · Harvard Medical School CSSA · Ohio State University College of Pharmacy Innovation Center · Pittsburg University Healthcare Incubator · Stanford University Healthcare Innovation Lab – Stanford Pipeline · Nest.Bio · Netherlands Innovation Center (NIC) · Frees Fund · JJLake Asia Future Innovation Challenger · Dane Capital · Aquillius · Simcere Therapeutical · Blue Ocean Capital Group · Chinese Entrepreneurs Organization at Duke (DukeCEO) · Penn Quakers Venture Club · Fish & Richardson · InnoStar · Porton · 聞藥事
· Yale Venture Club · The Hopkins Club for Innovation and Entrepreneurship · Asia America Innovation Alliance (AAIA) · GeneOnline · Life-Science Entrepreneurship and Plus (LEAP) · Huazhong University of Science and Technology (HUST) Boston Alumni Association · Tongji Medical College of HUST Boston Chapter · YuanBio Venture Capital · AAEA · PagodaTree Partners · AbbVie Ventures · F Prime · Amgen Venture · TOP Innovation Districts Lab · Greenberg Traurig · Baker Mckenzie · The Chinese Antibody Society (CAS) – Berkley QB3 – Startup Boston · 博藥 · 前途匯 · Biolink
· VIVA · Medicilon · ATLATL · Xingu Chuangfu · Alliance of Venture and Entrepreneurs Organization for Chinese Students Alumni at Harvard · Slush China · Danen Capital · Association d'Incubateur Franco-Chinois (AIFC) · Brandeis Impact · Chinese Entrepreneurs Organization · CuBio Innovation Center · HiMed · HuaSu Future · Eisai Innovation Inc · Regent Advisors · Enterprise Singapore · Massachusetts Biomedical Initiatives (MBI) · K2 Venture Partners · Singapore Economic Development Board (EDB) · Saudi Aribia NEOM Biotech Investment · P4 Precision Medicine Accelerator (UK)
17+4 Finalists 與 Roadshow-only 團隊
